Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up resu... by Hakim, J, Thompson, J, Kityo, C, Hoppe, A, Kambugu, A, van Oosterhout, J, Lugemwa, A, Siika, A, Mwebaze, R, Mweemba, A, Abongomera, G, Thomason, M, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up resu... by Hakim, J, Thompson, J, Kityo, C, Hoppe, A, Kambugu, A, van Oosterhout, J, Lugemwa, A, Siika, A, Mwebaze, R, Mweemba, A, Abongomera, G, Thomason, M, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N

Assessment of second-line antiretroviral regimens for HIV therapy in Africa. by Paton, N, Kityo, C, Hoppe, A, Reid, A, Kambugu, A, Lugemwa, A, van Oosterhout, J, Kiconco, M, Siika, A, Mwebaze, R, Abwola, M, Abongomera, G, Mweemba, A, Alima, H, Atwongyeire, D, Nyirenda, R, Boles, J, Thompson, J, Tumukunde, D, Chidziva, E, Mambule, I, Arribas, JR, Easterbrook, P, Hakim, J, Walker, A, Mugyenyi, P